OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Science Enterprises.
Location: United Kingdom, England, Oxford
Employees: 11-50
Total raised: $112.51M
Founded date: 2016
Investors 6
| Date | Name | Website |
| 05.07.2023 | British Pa... | britishpat... |
| - | BioCity | biocity.co... |
| - | Oxford Uni... | innovation... |
| 15.08.2024 | Syncona Pa... | synconaltd... |
| - | Oxford Sci... | oxfordscie... |
| 30.04.2022 | GV | gv.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.05.2023 | - | $12.51M | British Pa... |
| 06.05.2022 | Series B | $100M | - |
Mentions in press and media 19
| Date | Title | Description |
| 01.10.2024 | OMass Therapeutics Expands Development Team with Key Appointments in US and UK and Announces the Nomination of Clinical Candidate Against MC2 | PRESS RELEASE OMass Therapeutics Expands Development Team with Key Appointments in US and UK and Announces the Nomination of Clinical Candidate Against MC2 Oxford, United Kingdom – 1 October 2024 – OMass Therapeutics (‘OMass’ or ‘the Compan... |
| 21.08.2024 | Reliant AI: Gen AI-Based Data Analytics Company Raises $11.3 Million (Seed) | Reliant AI, a provider of gen AI-powered data analytics software, announced today it is launching out of stealth with $11.3 million in seed funding. This new funding round was co-led by Tola Capital and Inovia Capital, with participation fr... |
| 20.08.2024 | Gen AI Analytics Provider, Reliant AI, Launches With $11.3 Million in Seed Funding | Funding Co-Led by Inovia Capital & Tola Capital Brings AI-Driven Software to the Biopharma Industry With First Product Reliant Tabular Reliant AI, a provider of gen AI-powered data analytics software, announced today its launch out of s... |
| 20.08.2024 | GEN AI ANALYTICS PROVIDER, RELIANT AI, LAUNCHES WITH $11.3M IN SEED FUNDING | Funding Co-Led by Inovia Capital & Tola Capital Brings AI-Driven Software to the Biopharma Industry With First Product Reliant Tabular MONTREAL and BERLIN, Aug. 20, 2024 /PRNewswire/ - Reliant AI, a provider of gen AI-powered data analy... |
| 05.08.2024 | OMass Therapeutics Selected by Fierce Biotech as a “Fierce 15” Winner for 2024 | PRESS RELEASE OMass Therapeutics Selected by Fierce Biotech as a “Fierce 15” Winner for 2024 Oxford, United Kingdom – 5th August 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against hig... |
| 05.08.2024 | OMass Therapeutics Selected by Fierce Biotech as a “Fierce 15” Winner for 2024 | PRESS RELEASE OMass Therapeutics Selected by Fierce Biotech as a “Fierce 15” Winner for 2024 Oxford, United Kingdom – 5th August 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against hig... |
| 08.04.2024 | OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann | PRESS RELEASE OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann Oxford, United Kingdom – 8th April 2024 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicine... |
| 15.05.2023 | British Patient Capital Invests £10m in next generation drug development company OMass Therapeutics | 15 May 2023: British Patient Capital has made a £10 million investment into OMass Therapeutics, a platform therapeutic company that discovers and develops novel small molecule medicines in areas of high, unmet clinical need, to help advance... |
| 28.04.2022 | GV, Sanofi drive British biotech OMass to $100M series B, fueling work on undruggable targets | GV, Northpond Ventures and Sanofi Ventures have joined forces to pump $100 million into OMass Therapeutics, teeing the British biotech up to advance candidates against hard-to-hit targets toward the clinic. CEO Ros Deegan frames OMass’ plat... |
| 28.04.2022 | OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases | PRESS RELEASE OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases Financing led by new investors, GV, Northpond Ventures and Sanofi Ventures, with existing investors, Syncon... |
Show more